Alpha Cognition Inc. 8-K

What Happened

• On April 10, 2026, Alpha Cognition Inc. (the “Company”) entered into a Settlement Agreement and Mutual Release with Galantos Pharma GmbH i.L. (in liquidation) to extinguish contingent payment obligations tied to the Memogain Asset Purchase Agreement and related license arrangements.
• The Company agreed to a one‑time payment of EUR 5,214,220 to fully satisfy remaining royalty and milestone-related obligations; Galantos will waive and release the Company and its related parties from claims arising under the original agreement. This action was disclosed on the Company’s Form 8-K (Item 1.01).

Key Details

• Settlement date: April 10, 2026.
• Cash payment: EUR 5,214,220 (one-time).
• Discount: Company states the settlement is approximately a 40% discount to the estimated market value of remaining obligations, per management’s assessment.
• Contracts affected: Obligations under the Memogain Asset Purchase Agreement (Aug 23, 2013) as assumed under subsequent Memogain license agreements.

Why It Matters

• The settlement removes future contingent royalty and milestone payments tied to the Memogain assets, eliminating uncertainty and potential future cash outflows related to those obligations.
• It requires an immediate cash payment of €5.214M, which will affect the Company’s near-term cash position but replaces ongoing, potentially larger future liabilities (management estimates a roughly 40% savings versus projected obligations).
• For investors, this is a one-time operational/legal resolution that simplifies the Company’s legacy obligations; monitor subsequent filings or disclosures for any reported impact on cash balances or guidance.